JP2021534115A5 - - Google Patents
Info
- Publication number
- JP2021534115A5 JP2021534115A5 JP2021506716A JP2021506716A JP2021534115A5 JP 2021534115 A5 JP2021534115 A5 JP 2021534115A5 JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021506716 A JP2021506716 A JP 2021506716A JP 2021534115 A5 JP2021534115 A5 JP 2021534115A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- heteroaryl
- cycloalkyl
- heterocyclyl
- aralkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862718929P | 2018-08-14 | 2018-08-14 | |
| US62/718,929 | 2018-08-14 | ||
| US201862775797P | 2018-12-05 | 2018-12-05 | |
| US62/775,797 | 2018-12-05 | ||
| US201962836511P | 2019-04-19 | 2019-04-19 | |
| US62/836,511 | 2019-04-19 | ||
| PCT/US2019/046411 WO2020036999A1 (en) | 2018-08-14 | 2019-08-13 | Treatment of b cell malignancies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534115A JP2021534115A (ja) | 2021-12-09 |
| JP2021534115A5 true JP2021534115A5 (enExample) | 2022-08-19 |
Family
ID=69525845
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021506716A Pending JP2021534115A (ja) | 2018-08-14 | 2019-08-13 | Ｂ細胞悪性腫瘍の処置 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210299134A1 (enExample) |
| EP (1) | EP3836935A4 (enExample) |
| JP (1) | JP2021534115A (enExample) |
| KR (1) | KR20210043635A (enExample) |
| CN (1) | CN112888441A (enExample) |
| AU (1) | AU2019321432A1 (enExample) |
| BR (1) | BR112021002760A2 (enExample) |
| CA (1) | CA3109184A1 (enExample) |
| IL (1) | IL280726A (enExample) |
| MA (1) | MA53236A (enExample) |
| MX (1) | MX2021001606A (enExample) |
| SG (1) | SG11202101450VA (enExample) |
| TW (1) | TW202021591A (enExample) |
| WO (1) | WO2020036999A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107501241B (zh) | 2011-03-28 | 2020-10-13 | 梅制药公司 | 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途 |
| EP3630118A4 (en) | 2017-05-23 | 2021-03-31 | MEI Pharma, Inc. | COMBINATION THERAPY |
| MX2020001727A (es) | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014500275A (ja) * | 2010-12-06 | 2014-01-09 | フォリカ，インコーポレイテッド | 禿頭症を治療するため、および毛髪の成長を促進するための方法 |
| CN107501241B (zh) * | 2011-03-28 | 2020-10-13 | 梅制药公司 | 化合物、含有其的药物组合物以及它们在治疗增生性疾病中的用途 |
| CA2979671C (en) * | 2014-09-23 | 2020-03-10 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
| WO2017007658A1 (en) * | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| WO2017035234A1 (en) * | 2015-08-24 | 2017-03-02 | Epizyme, Inc. | Method for treating cancer |
| US11365252B2 (en) * | 2016-07-20 | 2022-06-21 | University Of Utah Research Foundation | CD229 CAR T cells and methods of use thereof |
| CN109982687A (zh) * | 2016-09-19 | 2019-07-05 | 梅制药公司 | 联合疗法 |
| WO2018060833A1 (en) * | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
| WO2018082444A1 (zh) * | 2016-11-02 | 2018-05-11 | 叶宝欢 | 吡唑并嘧啶化合物作为pi3k抑制剂及其应用 |
| MX2020001727A (es) * | 2017-08-14 | 2020-03-20 | Mei Pharma Inc | Terapia de combinacion. |
-
2019
- 2019-08-13 WO PCT/US2019/046411 patent/WO2020036999A1/en not_active Ceased
- 2019-08-13 MA MA053236A patent/MA53236A/fr unknown
- 2019-08-13 CA CA3109184A patent/CA3109184A1/en active Pending
- 2019-08-13 EP EP19849451.0A patent/EP3836935A4/en not_active Withdrawn
- 2019-08-13 AU AU2019321432A patent/AU2019321432A1/en not_active Abandoned
- 2019-08-13 KR KR1020217007417A patent/KR20210043635A/ko not_active Ceased
- 2019-08-13 JP JP2021506716A patent/JP2021534115A/ja active Pending
- 2019-08-13 MX MX2021001606A patent/MX2021001606A/es unknown
- 2019-08-13 US US17/268,052 patent/US20210299134A1/en not_active Abandoned
- 2019-08-13 SG SG11202101450VA patent/SG11202101450VA/en unknown
- 2019-08-13 CN CN201980067607.2A patent/CN112888441A/zh active Pending
- 2019-08-13 BR BR112021002760-2A patent/BR112021002760A2/pt not_active IP Right Cessation
- 2019-08-14 TW TW108128967A patent/TW202021591A/zh unknown
-
2021
- 2021-02-08 IL IL280726A patent/IL280726A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021517116A5 (enExample) | ||
| JP2024507938A5 (enExample) | ||
| KR101671761B1 (ko) | 이미다조옥사진 화합물에 의한 항종양 효과 증강제 | |
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JP2020531414A5 (enExample) | ||
| JP2018517686A5 (enExample) | ||
| JP2015536986A5 (enExample) | ||
| BRPI0916694B1 (pt) | uso de neratinibe em combinação com capecitabina para tratar câncer de mama metastático de erbb-2 positivo, kit e produto compreendendo os mesmos | |
| JP2018526376A5 (enExample) | ||
| RU2020109775A (ru) | Комплексная терапия | |
| JP2014524469A5 (enExample) | ||
| JP2022540421A5 (enExample) | ||
| JP2012528099A (ja) | Ｐｌｋ１阻害剤および抗腫瘍剤を含む治療組合せ | |
| JP2018503610A5 (enExample) | ||
| CN101484443B (zh) | 放射线治疗增强剂 | |
| JP2021534116A5 (enExample) | ||
| US20130101680A1 (en) | Radiotherapy enhancer | |
| JP2016502540A5 (enExample) | ||
| JP2021534114A5 (enExample) | ||
| RU2007104176A (ru) | Синтез и применение (-)-бета-элемена, (-)-бета-элеменала, (-)-бета-элеменола, фторида (-)-бета-элемена и их аналогов, а также промежуточных продуктов и композитов | |
| JP5976923B2 (ja) | イリノテカン塩酸塩水和物を含有する抗腫瘍剤 | |
| AU2022347609A1 (en) | Methods of cancer treatment using a combination of btk inhibitors and pi3 kinase inhibitors | |
| JP2023514426A5 (enExample) | ||
| JP2014034531A (ja) | Ｈｓｐ９０阻害剤とゲムシタビンの組み合わせ | |
| JPH0120128B2 (enExample) |